Please ensure Javascript is enabled for purposes of website accessibility

Peak Proteins Becomes Part of Sygnature Discovery

Alderley Park Cheshire Science Corridor 27/04/2022

Drug discovery firms join forces in acquisition

Peak Proteins are now part of Sygnature Discovery; a world-leading integrated discovery and preclinical solutions provider.

Following an extensive partnership between the two companies, this deal will enable seamless integration of Peak Proteins main services into protein production and related structure determination projects within Sygnature. Peak Proteins will continue to operate out of their new research facility in Macclesfield, near Sygnature’s Alderley Park site. The Peak Proteins leadership team will also remain with the business.

In January 2016 Sygnature’s shareholders took a significant stake in the business and since then, Steve Young, VP of Business Development and Stuart Onions, SVP of Alliance Management at Sygnature have been board members of Peak Proteins. During this period, the two companies working together, have supported a number of integrated drug discovery programmes.

Mark Abbott, CEO of Peak Proteins, commented: “We have always valued Sygnature Discovery’s support and are now really pleased to be joining them. It will enable us to work more closely on integrated projects in addition to our existing client base where we provide both proteins and protein structural information on a very wide range of proteins to clients across the world.”

Sygnature Discovery’s CEO, Simon Hirst, stated: ‘We are delighted to welcome Peak Proteins and its talented scientists to the Sygnature family. Accessing high quality proteins efficiently is often a major stumbling for projects and protein structural information is still the gold standard when it comes to drug design. The closer integration of Peak Proteins into our projects will be extremely powerful in driving programmes forward.’

The acquisition is part of Sygnature’s strategic plan to continuously invest in the expansion of their drug discovery capabilities. Steve Young, Sygnature Discovery VP of Business Development, says that “The Peak Proteins expertise will sit perfectly alongside our HTS and extensive biophysics capabilities. Their world-class expertise in protein crystallography will enhance our fragment screening and analysis activities, as well as our structure-based drug design work.”

This transaction represents the fourth acquisition that Sygnature Discovery has made in the last four years, and the first since Five Arrows Principal Investments made a significant equity investment in the company in 2021.